Introduction: Breast cancer is a leading cause of cancer-related morbidity and mortality worldwide, with genetic polymorphisms playing a crucial role in individual susceptibility. Understanding the distribution of these variants and their associated drug side effects among different Iranian ethnic groups may provide valuable insights for personalized medicine.
Methods: The pharmacogenetic software MegaGen was used to analyze polymorphism data and identify drug side effects with a genetic basis. Data obtained from the NCBI database, including polymorphisms, sequences, and related publications, were organized and analyzed using this software.
Results: Drug side effects can vary between individuals due to genetic differences affecting drug metabolism and response. In breast cancer treatment, it is essential to perform genetic testing prior to prescribing drugs or initiating therapy to identify common polymorphisms, such as rs80359405, rs2219594, and rs2227944 in genes including BRCA2. Detecting these variants enables the selection of medications with lower risk of adverse effects, thereby improving treatment safety and efficacy.
Conclusion: Among the domestic and imported drugs related to breast cancer, there are no side effects in BRCA2 gene polymorphisms.